sorafenib has been researched along with Kahler Disease in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Abou-Zeid, LA; Ashour, HF; El-Sayed, MA; Selim, KB | 1 |
| Fox, C; Jemielita, T; Liaw, KL; Pettersson, A; Salomonsson, S; Widman, L | 1 |
| Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A | 1 |
| Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA | 1 |
| Anel, A; Azaceta, G; Galán-Malo, P; Jarauta, V; López-Royuela, N; Marzo, I; Naval, J; Palomera, L; Pardo, J; Ramírez-Labrada, A | 1 |
| Liu, BL; Liu, X; Qi, MY; Xu, B; Zhou, NC | 1 |
| Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Adjei, AA; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE | 1 |
| Anderson, KC; Podar, K | 1 |
| Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B | 1 |
| Ceder, S; Kharaziha, P; Panaretakis, T; Sanchez, C | 1 |
| Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D | 1 |
| Burton, A | 1 |
2 review(s) available for sorafenib and Kahler Disease
| Article | Year |
|---|---|
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thalidomide | 2016 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
2 trial(s) available for sorafenib and Kahler Disease
| Article | Year |
|---|---|
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome | 2013 |
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2014 |
9 other study(ies) available for sorafenib and Kahler Disease
| Article | Year |
|---|---|
1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Chalcones; Humans; Molecular Structure; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2020 |
Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Registries; Sorafenib; Sweden | 2021 |
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibitors; Caspases; Cell Proliferation; Flow Cytometry; Humans; Mitochondria; Multiple Myeloma; Necrosis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2015 |
[Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226].
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib | 2014 |
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Humans; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Disease Models, Animal; DNA Primers; Female; Flow Cytometry; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Multitargeted therapies for multiple myeloma.
Topics: Animals; Disease Models, Animal; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2013 |
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemokine CXCL12; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Polymerization; Pyrazines; Sorafenib; Syndecan-1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Multiple Myeloma; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2006 |